These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 16945426

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor.
    Lobito AA, Yang B, Lopes MF, Miagkov A, Adams RN, Palardy GR, Johnson MM, McFarland HI, Recher M, Drachman DB, Lenardo MJ.
    Eur J Immunol; 2002 Jul; 32(7):2055-67. PubMed ID: 12115627
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis.
    Schaffert H, Pelz A, Saxena A, Losen M, Meisel A, Thiel A, Kohler S.
    Eur J Immunol; 2015 May; 45(5):1339-47. PubMed ID: 25676041
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor.
    Rosenberg JS, Oshima M, Atassi MZ.
    J Immunol; 1996 Oct 01; 157(7):3192-9. PubMed ID: 8816433
    [Abstract] [Full Text] [Related]

  • 13. Animal models of myasthenia gravis.
    Christadoss P, Poussin M, Deng C.
    Clin Immunol; 2000 Feb 01; 94(2):75-87. PubMed ID: 10637092
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Decreased bone mineral density in experimental myasthenia gravis in C57BL/6 mice.
    Oshima M, Iida-Klein A, Maruta T, Deitiker PR, Atassi MZ.
    Autoimmunity; 2017 Sep 01; 50(6):346-353. PubMed ID: 28850269
    [Abstract] [Full Text] [Related]

  • 16. Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis.
    Nessi V, Nava S, Ruocco C, Toscani C, Mantegazza R, Antozzi C, Baggi F.
    J Immunol; 2010 Nov 01; 185(9):5656-67. PubMed ID: 20881192
    [Abstract] [Full Text] [Related]

  • 17. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
    Ulusoy C, Çavuş F, Yılmaz V, Tüzün E.
    Immunol Invest; 2017 Jul 01; 46(5):490-499. PubMed ID: 28375749
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
    Tüzün E, Saini SS, Morgan BP, Christadoss P.
    J Neuroimmunol; 2006 Dec 01; 181(1-2):29-33. PubMed ID: 17056125
    [Abstract] [Full Text] [Related]

  • 20. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ, Oshima M, Deitiker P.
    Crit Rev Immunol; 2001 Dec 01; 21(1-3):1-27. PubMed ID: 11642597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.